Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice

Kazunori Shibuya, Tomoaki Kuwaki, Hiromichi Akahori, Takashi Kato, Hiroshi Miyazaki

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We examined the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on the development of L-8057, a murine megakaryoblastic leukemia that expresses the thrombopoietin receptor c-Mpl, in mice. PEG-rHuMGDF administration prolonged survival of L-8057 leukemic mice, in which L-8057 cell growth in the spleen was decreased. L-8057 cells harvested from PEG-rHuMGDF-treated leukemic mice had decreased ability to generate leukemic colonies in vitro as well as to induce leukemia in vivo. PEG-rHuMGDF administration also resulted in prolonged survival of mice transplanted with a c-Mpl-expressing erythroleukemia, but had no effect on survival of mice transplanted with a myeloblastic leukemia that does not possess c-Mpl. Thus, PEG-rHuMGDF suppresses the development of c-Mpl-expressing leukemia in vivo in mice.

Original languageEnglish
Pages (from-to)941-946
Number of pages6
JournalLeukemia Research
Volume28
Issue number9
DOIs
Publication statusPublished - 2004 Sep 1

Keywords

  • AML
  • BSA
  • FCS
  • L-CFU
  • PEG-rHuMGDF
  • TPO
  • WBC
  • acute myelogenous leukemia
  • bovine serum albumin
  • fetal calf serum
  • leukemia colony-forming unit
  • pegylated recombinant human megakaryocyte growth and development factor
  • thrombopoietin
  • white blood cell

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Pegylated recombinant human megakaryocyte growth and development factor suppresses the development of megakaryoblastic leukemia in mice'. Together they form a unique fingerprint.

  • Cite this